Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease

Heart Lung and Circulation

Volumn 25, Issue 5, 2016, Pages 459-465

  Wang, Xiaofang ^a   Zhao, Xiaoyan ^a   Li, Ling ^a   Yao, Haimu ^a   Jiang, Yan ^b   Zhang, Jinying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Coronary artery plaque; Ezetimibe; High sensitivity C reactive protein; Interleukin 6; Matrix metalloproteinase 9; Rosuvastatin

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE PLUS ROSUVASTATIN; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; EZETIMIBE; IL6 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; EVENING DOSAGE; FEMALE; HEART DEATH; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; HYPERLIPIDEMIA; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; UNSTABLE ANGINA PECTORIS; BLOOD; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; FOLLOW UP; INTERVENTIONAL ULTRASONOGRAPHY; METABOLISM; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC;

AGED; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; ROSUVASTATIN CALCIUM; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84949658883     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2015.10.012     Document Type: Article

References (14)

1. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
3. Schwartz G.G., Olssen A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., et al. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACLE study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
4. Sudhop T., Lütjohann D., Kodal A., Igel M., Tribble D.L., Shah S., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943-1948.
5. van Heek M., Farley C., Compton D.S., Hoos L., Davis H.R. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001, 134:409-417.
6. Califf R.M., Harrington R.A., Blazing M.A. Premature release of data from clinical trials of ezetimibe. N Engl Med 2009, 361:712-717.
7. Patrick J.E., Kosoglou T., Stauber K.L., Alton K.B., Maxwell S.E., Zhu Y., et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002, 30:430-437.
8. Kastelein J.J., Sager P.T., de Groot E., Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005, 149:234-239.
9. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015, 372:2387-2397.
10. Ference B.A., Majeed F., Penumetcha R., Flack J.M., Brook R.D. Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015, 65:1552-1561.
11. Li H., Hontani N., Toshida I., Oka M., Sato T., Akiba S. Group IVA phospholipase A2-associated production of MMP-9 in macrophages and formation of atherosclerotic lesions. Biol Pharm Bull 2008, 31:363-368.
12. Devaraj S., Autret B., Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006, 98:641-643.
13. Sager P.T., Capece R., Lipka L., Strony J., Yang B., Suresh R., et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005, 179:361-367.
14. Gomma A.H., Hirschfield G.M., Gallimore J.R., Lowe G.D., Pepys M.B., Fox K.M. Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J 2004, 147:1071-1077.